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Supplementary Figure 1. LOH events in NAT2 are present in early stages of colorectal tumor progression
Each bar represents the percentage of allelic loss reported for a particular SNV in the genotyped CRC cohort, where a total of 17 LOH events were identified (ABP1 = 3; AKR7A2 = 1; NAT2 = 12; SULT1C3 = 1). Within each bar, the fraction of samples belonging to each stage of tumor progression is shown.
Supplementary Figure 2. A cell-based screen to identify cytotoxic compounds metabolized by NAT2
A set of 176 compounds were identified as potential NAT2 substrates by informatic analyses of a library of 189,018 chemical structures. These compounds were incubated at three concentrations (0.5 μM, 2 μM and 10 μM) with vector control (-) or rapid NAT2 expressing (+) RKO cells for 3 days and cell viability was scored in an MTT assay. The data for each compound are grouped with color intensity representing percentage growth inhibition relative to untreated controls (right panel, A). Black rectangle, hit compound (APA). Error bars in the center of the well, S.D. of two biological replicates.
Supplementary Figure 3.
Silencing of endogenous NAT2 sensitizes HCT116 cells to APA treatment HCT116 cells were transfected with a pool of siRNA targeting NAT2. Non-target RNA control, mock transfection and non-transfected cell control were included in the experiment. Following siRNA-mediated silencing of NAT2, cells were treated with a APA and b 5-FU. Mean and S.D. of 3 independent experiments. Data were analyzed using two-way ANOVA. n.s., P = 0.4978, *, P = 0.0355 and ***, P = 0.006 (1.0 µM) and 0.0008 (1.5 µM). c HCT116 cells show reduced transcript levels of NAT2 following siRNA-mediated targeting. Cells were mock-treated, non-target RNA treated and treated with target siRNA against NAT2. A result of qPCR analysis of two independent experiments is shown, with 3 technical repeats in each. Means of normalized expression levels toward mock-treatment.
Supplementary Figure 4.
Kinome inhibition profiles of APA and its NAT2 metabolite NAPA identifies preferential APA kinase targets and differential binding to AURKA a The human kinome was assessed for binding affinity to APA and NAPA at 10 µM concentration (468 kinases in the scanMAX Kinase Assay Panel, DiscoverX). The family stratification of kinases is shown as a cladogram. Circles visualize the binding affinity of NAPA and APA towards each kinase with a higher intensity of blue corresponding to a higher binding affinity. Arrowheads point to kinases, for which the binding affinity of NAPA is ≤25% than the binding affinity of APA. b The amount of recovered AURKA in KdELECT Kinase Assay in presence of APA or NAPA by compound concentration. The inhibitory binding constant for APA was estimated from two independent experiments, whereas NAPA did not show substantial change in binding affinity in the tested concentration range. One single data point from one experiment at a concentration 18.5 µM of APA was excluded as an outlier. c Thermal shift assay for human recombinant AURKA in the presence of APA and the selective inhibitor S1451. Melting temperatures were obtained by calculating the first derivative of the tryptophan fluorescence ratio at 350 nm and 330 nm and are shown for AURKA in the presence of S1451 (blue) and APA (yellow). Figure 5 . siRNA-mediated knock-down reduces transcript levels of DYRK1A, AURKA or CDK7 and AURKA protein levels in RKO and DLD-1 cells RKO a and DLD-1 b cells show reduced transcript levels of DYRK1A, AURKA and CDK7 following treatment with siRNA targeting the respective kinase. Cells were mock-treated, nontarget RNA treated and treated with target siRNA against DYRK1A, AURKA or CDK7. A result of qPCR analysis of two independent experiments is shown, with 3 technical repeats in each. Means of normalized expression levels toward mock-treatment. c siRNA-mediated knockdown of AURKA, reduces the protein levels of AURKA in both RKO and DLD-1 cells. RKO and DLD-1 cells were subjected to immunoblot analysis with different antibodies against total AURKA and PCNA (loading control) following mock-treatment, non-target RNA control and siRNA targeting AURKA. d Protein expression levels of AURKA are reduced following siRNA-mediated silencing of AURKA in both RKO and DLD-1. Quantification of two immunoblot analyses performed as in c; AURKA protein levels were normalized to the loading control (PCNA) and relative expression towards mock treatment is shown as mean value. Figure 6 . APA reduces AURKA phosphorylation and causes mitotic arrest in NAT2-deficient cells a Phospho-Aurora A levels in DMSO and S1451-treated DLD-1 cells. The pAURKA level (red) was detected in mitotic DLD-1 cells but not in parental DLD-1 cells and NAT2 clones treated with the selective Aurora A kinase inhibitor S1451 (10 µM). Mitotic spindles were visualized by α-tubulin staining (green). Representative images of three independent repeats are shown for each cell type. Scale bar, 10 µm. b APA causes mitotic arrest in NAT2-deficient cells. Mitotic spindles were visualized by α-tubulin staining (green) and mitotic arrest was shown in histone H3 pSer10 positive cells (pink). The effect of APA was compared to nocodazole (100 ng/mL), a microtubule inhibitor that also causes mitotic arrest. Representative images of three independent repeats are shown for each cell type. Scale bar, 50 µm. c Quantification of cells with mitotic spindles after treatment with DMSO, APA (2 µM) or nocodazole (100 ng/mL). Mean and S.D. (error bars) of 3 independent experiments. Data were analyzed using two-way ANOVA. n.s., P = 0.1857 and ****, P < 0.0001. Supplementary Figure 7 . APA treatment impairs the growth of slow NAT2 tumors a, b The relative tumor volume of slow, but not rapid NAT2 tumors is decreased after 5 days of treatment with either liposomal or free APA. Tumor size was measured using a caliper and normalized to day 0 before treatment start. Data were analyzed using two-way ANOVA, n.s., P = 0.7734 (Liposomal APA) and 0.7157 (Free drug), **, P = 0.0028, ***, P = 0.0009. Mean and s.e.m. (error bars) shown for one representative experiment conducted with 10 mice for each treatment group. c. Treatment with APA as a free drug has no effect on tumor volume ratio. The rate at which slow NAT2 tumors grow compared to rapid NAT2 tumors is not significant in the group of animals treated with APA after 5 days. Data were analyzed using two-way ANOVA, n.s., P = 0.5708. Data points from one representative experiment conducted in 10 mice. d Animal weight remained stable during APA treatment. The weight of each animal was monitored during the course of the experiment. Data were analyzed using two-way ANOVA, n.s., P = 0. Figure 2A , b Myc and Tubulin in Figure 2B , c AURKA, Histone 3, Histone H3 Ser10 and PCNA in Figure 3G , and d PCNA and AURKA shown in Figure S5 . Exposure times are shown for each blot. 
Supplementary

Supplementary 
